Walgreens 2004 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2004 Walgreens annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 53

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53

21
In May 2004, the FASB issued FSP FAS 106-
2, "Accounting and Disclosure Requirements Related to the Medicare Prescription
Drug, Improvements and Modernization Act of 2003." This statement requires the company to disclose the effects of the Act and
to assess the imp act of the subsidy on the accumulated postretirement benefit obligation and net periodic postretirement benefit
cost in the first interim or annual period beginning after June 15, 2004. The effective date for the company is the quarter ending
November 30, 2004. We are currently evaluating the impact of the Act on our postretirement benefit plan.
Cautionary Note Regarding Forward-Looking Statements
Certain statements and projections of future results made in this report constitute forward-looking information that is based on
current market, competitive and regulatory expectations that involve risks and uncertainties. Those risks and uncertainties include
changes in economic conditions generally or in the markets served by the company; consumer preferenc
es and spending patterns;
changes in or the introduction of new state or federal legislation or regulations; the availability and cost of real estate and
construction; competition; and risks associated with new business endeavors. Please see page 6 of this Form 10-K/A for a
discussion of certain other important factors as they relate to forward-looking statements. Actual results could differ materially.
Item 7A. Qualitative and Quantitative Disclosures about Market Risk
Management does not believe that there is any material market risk exposure with respect to derivative or other
financial instruments that would require disclosure under this item.